Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis

Floor van Wijk; Jerome Waterval; Koen van Aerde; Stefanie S. Henriet; F. J. Anton Meijer; Lennaert C. Borra; Rob E. Aarnoutse; Jakko van Ingen

doi:10.1128/AAC.01203-19

Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis

Floor van Wijk, Jerome Waterval, Koen van Aerde, Stefanie S. Henriet, F. J. Anton Meijer, Lennaert C. Borra, Rob E. Aarnoutse, Jakko van Ingen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Mycobacterium abscessus is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe infection. We treated four children with M. abscessus otomastoiditis with a structured regimen of topical imipenem and tigecycline, intravenous imipenem and tigecycline, and oral clofazimine and azithromycin and adjunctive surgery. This structured approach led to cure, with 1 year of follow-up after treatment. Adverse events were frequent, mostly caused by tigecycline.

Original language	English
Article number	e01203-19
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	64
Issue number	1
DOIs	https://doi.org/10.1128/AAC.01203-19
Publication status	Published - Jan 2020

Keywords

Mycobacterium abscessus
mastoiditis
otitis
tigecycline
clofazimine
Mycobacterium
experimental therapeutics
otitis media
pediatric drug therapy
CLOFAZIMINE
TIGECYCLINE
AMIKACIN

Access to Document

10.1128/AAC.01203-19

Cite this

@article{6ac87cc30da24aa88594d64edb9e4de7,

title = "Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis",

abstract = "Mycobacterium abscessus is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe infection. We treated four children with M. abscessus otomastoiditis with a structured regimen of topical imipenem and tigecycline, intravenous imipenem and tigecycline, and oral clofazimine and azithromycin and adjunctive surgery. This structured approach led to cure, with 1 year of follow-up after treatment. Adverse events were frequent, mostly caused by tigecycline.",

keywords = "Mycobacterium abscessus, mastoiditis, otitis, tigecycline, clofazimine, Mycobacterium, experimental therapeutics, otitis media, pediatric drug therapy, CLOFAZIMINE, TIGECYCLINE, AMIKACIN",

author = "{van Wijk}, Floor and Jerome Waterval and {van Aerde}, Koen and Henriet, {Stefanie S.} and Meijer, {F. J. Anton} and Borra, {Lennaert C.} and Aarnoutse, {Rob E.} and {van Ingen}, Jakko",

year = "2020",

month = jan,

doi = "10.1128/AAC.01203-19",

language = "English",

volume = "64",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "1",

}

TY - JOUR

T1 - Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis

AU - van Wijk, Floor

AU - Waterval, Jerome

AU - van Aerde, Koen

AU - Henriet, Stefanie S.

AU - Meijer, F. J. Anton

AU - Borra, Lennaert C.

AU - Aarnoutse, Rob E.

AU - van Ingen, Jakko

PY - 2020/1

Y1 - 2020/1

N2 - Mycobacterium abscessus is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe infection. We treated four children with M. abscessus otomastoiditis with a structured regimen of topical imipenem and tigecycline, intravenous imipenem and tigecycline, and oral clofazimine and azithromycin and adjunctive surgery. This structured approach led to cure, with 1 year of follow-up after treatment. Adverse events were frequent, mostly caused by tigecycline.

AB - Mycobacterium abscessus is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe infection. We treated four children with M. abscessus otomastoiditis with a structured regimen of topical imipenem and tigecycline, intravenous imipenem and tigecycline, and oral clofazimine and azithromycin and adjunctive surgery. This structured approach led to cure, with 1 year of follow-up after treatment. Adverse events were frequent, mostly caused by tigecycline.

KW - Mycobacterium abscessus

KW - mastoiditis

KW - otitis

KW - tigecycline

KW - clofazimine

KW - Mycobacterium

KW - experimental therapeutics

KW - otitis media

KW - pediatric drug therapy

KW - CLOFAZIMINE

KW - TIGECYCLINE

KW - AMIKACIN

U2 - 10.1128/AAC.01203-19

DO - 10.1128/AAC.01203-19

M3 - Article

C2 - 31611360

SN - 0066-4804

VL - 64

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 1

M1 - e01203-19

ER -